- CRSP +0.32%
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at third-quarter-end, with a position valued at approximately $634 million. ARK decreased its exposure slightly in Q3, reducing its holdings from 10.18 million to 9.79 million shares.
As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target of $80, the stock has nearly a 50% upside.
On November 12, Citi analyst Yigal Nochomovitz reaffirmed his bullish stance on CRISPR Therapeutics AG (NASDAQ:CRSP) with a Buy rating but lowered his price from $87 to $77.
This action came closely after the company reported its Q3 results on November 10 and announced positive phase 1 clinical data for CTX310 on November 8. CTX310 is an investigational gene-editing therapy that targets the ANGPTL3 gene to potentially lower triglycerides (TG) and low-density lipoprotein (LDL) cholesterol in patients with severe or refractory dyslipidemia. This progress paves the way for the company to capitalize on opportunities in cardiovascular disease prevention, potentially.
On the significance of the positive trial result, Naimish Patel, M.D., Chief Medical Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), stated:
“The publication and presentation of these Phase 1 results mark an important milestone for CRISPR Therapeutics and for the field of in vivo gene editing. For the first time, we’ve shown that a single-course in vivo CRISPR treatment can safely and durably lower ANGPTL3, leading to clinically meaningful reductions in triglycerides and LDL. These data provide strong support for continued advancement of CTX310 and our broader cardiovascular gene-editing portfolio.”
In its Q3 2025 results, the company’s net loss widened to $106.4 million from $85.9 million in Q3 2024, driven by higher collaboration expenses. However, the balance sheet remains robust with cash and cash equivalents of $1.94 billion as of the end of September. The company also reported solid progress since the launch of its sickle cell disease and beta-thalassemia therapy CASGEVY.
CRISPR Therapeutics AG (NASDAQ:CRSP) is a leading gene editing company focused on developing transformative medicines for serious diseases.
While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Story ContinuesREAD NEXT: 30 Most Fantastic Stocks Every Investor Should Pay Attention To and 10 Hottest Smid-Cap Stocks So Far In 2025.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy Privacy Dashboard More Info
